Literature DB >> 26117714

TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects.

L Probert1.   

Abstract

Tumor necrosis factor (TNF) is the prototypic pro-inflammatory cytokine. It is central to host defense and inflammatory responses but under certain circumstances also triggers cell death and tissue degeneration. Its pleiotropic effects often lead to opposing outcomes during the development of immune-mediated diseases, particularly those affecting the central nervous system (CNS). The reported contradictions may result from lack of precision in discussing TNF. TNF signaling comprises at minimum a two-ligand (soluble and transmembrane TNF) and two-receptor (TNFR1 and TNFR2) system, with ligands and receptors both differentially expressed and regulated on different cell types. The "functional multiplicity" this engenders is the focus of much research, but there is still no general consensus on functional outcomes of TNF signaling in general, let alone in the CNS. In this review, evidence showing the effects of TNF in the CNS under physiological and pathophysiological conditions is placed in the context of major advances in understanding of the cellular and molecular mechanisms that govern TNF function in general. Thus the roles of TNF signaling in the CNS shift from the conventional dichotomy of beneficial and deleterious, that mainly explain effects under pathological conditions, to incorporate a growing number of "essential" and "desirable" roles for TNF and its main cellular source in the CNS, microglia, under physiological conditions including regulation of neuronal activity and maintenance of myelin. An improved holistic view of TNF function in the CNS might better reconcile the expansive experimental data with stark clinical evidence that reduced functioning of TNF and its dominant pro-inflammatory receptor, TNFR1, are risk factors for the development of multiple sclerosis. It will also facilitate the safe translation of basic research findings from animal models to humans and propel the development of more selective anti-TNF therapies aimed at selectively inhibiting deleterious effects of this cytokine while maintaining its essential and desirable ones, in the periphery and the CNS.
Copyright © 2015 The Author. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  TNF; inflammation; microglia; multiple sclerosis; neurodegeneration; therapy

Mesh:

Substances:

Year:  2015        PMID: 26117714     DOI: 10.1016/j.neuroscience.2015.06.038

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  160 in total

1.  Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis.

Authors:  Roman Fischer; Tanja Padutsch; Valerie Bracchi-Ricard; Kayla L Murphy; George F Martinez; Niky Delguercio; Nicholas Elmer; Maksim Sendetski; Ricarda Diem; Ulrich L M Eisel; Richard J Smeyne; Roland E Kontermann; Klaus Pfizenmaier; John R Bethea
Journal:  Brain Behav Immun       Date:  2019-06-17       Impact factor: 7.217

2.  TNF-α receptor 1 knockdown in the subfornical organ ameliorates sympathetic excitation and cardiac hemodynamics in heart failure rats.

Authors:  Yang Yu; Shun-Guang Wei; Robert M Weiss; Robert B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-14       Impact factor: 4.733

Review 3.  Evaluation of Possible Consequences of Zika Virus Infection in the Developing Nervous System.

Authors:  Lais Takata Walter; Guilherme Shigueto Vilar Higa; Juliane Midori Ikebara; Danila Vedovello; Felipe Scassi Salvador; Silvia Honda Takada; Erika Reime Kinjo; Benjamin J Whalley; Márcia Aparecida Sperança; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2017-02-11       Impact factor: 5.590

4.  Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.

Authors:  Claudia Mara Ribeiro; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Tamires Flauzino; Damacio Ramón Kaimen-Maciel; Andréa Name Colado Simão; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-09-26       Impact factor: 4.575

Review 5.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

6.  Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis.

Authors:  Sayonara Rangel Oliveira; Tamires Flauzino; Beatriz Sardinha Sabino; Ana Paula Kallaur; Daniela Frizon Alfieri; Damacio Ramon Kaimen-Maciel; Helena Kaminami Morimoto; Elaine Regina Delicato de Almeida; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Isaias Dichi; Andréa Name Colado Simão
Journal:  Metab Brain Dis       Date:  2018-05-24       Impact factor: 3.584

7.  Neuroinflammation in psychiatric disorders: An introductory primer.

Authors:  Geoffrey A Dunn; Jennifer M Loftis; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2020-07-01       Impact factor: 3.533

8.  Resistin deficiency in mice has no effect on pulmonary responses induced by acute ozone exposure.

Authors:  Shehla S Razvi; Jeremy B Richards; Farhan Malik; Kevin R Cromar; Roger E Price; Cynthia S Bell; Tingting Weng; Constance L Atkins; Chantal Y Spencer; Katherine J Cockerill; Amy L Alexander; Michael R Blackburn; Joseph L Alcorn; Ikram U Haque; Richard A Johnston
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-18       Impact factor: 5.464

Review 9.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

10.  TNF-α/TNFR2 Regulatory Axis Stimulates EphB2-Mediated Neuroregeneration Via Activation of NF-κB.

Authors:  Paul D Pozniak; Armine Darbinyan; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-11-04       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.